Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a clinical?stage biopharmaceutical company with a portfolio of innovative, late?stage product candidates targeting neurological diseases, including rare disorders, today announced that it has commenced an underwritten public offering of $300 million of its common shares. All of the common shares to be sold in the offering will be offered by Biohaven. In addition, Biohaven expects to grant the underwriters a 30-day option to purchase up to an additional $45 million of common shares at the public offering price, less underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

Goldman Sachs & Co. LLC and Piper Jaffray & Co. are acting as joint book-running managers of the offering.